Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma

In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]

read more

Atezolizumab and bevacizumab in patients with advanced non-clear cell renal cell carcinoma

Dr Rana McKay from University of California in San Diego, USA and Dr Monty Pal from the City of Hope Medical Centre in California, USA share in a discussion on the study design and results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal […]

read more

IKCS 2019: Novel biomarkers for prognosis of kidney cancer

Two presentations at the International Kidney Cancer Symposium 2019 in Miami earlier this month discuss the use of two novel biomarkers for imaging metastatic renal cell carcinoma (RCC). Dr Allan Pantuck from the University of California, Los Angeles spoke about carbonic anhydrase IX (CAIX) as a non-invasive molecular marker for clear cell RCC. Tumours that […]

read more

Phase Ib cabozantinib plus atezolizumab combination study now open to kidney cancer patients in the UK

Based on promising efficacy findings, the COSMIC-021 clinical trial has been expanded from the original two indications (non-small cell lung cancer (NSCLC) and prostate cancer) and is now open to patients with renal cell carcinoma (RCC), urothelial cancer, breast cancer and ovarian cancer. The phase 1b, open-label trial assesses the combination of cabozantinib (Cabometyx) and […]

read more

Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

Results from this phase III trial of atezolizumab plus bevacizumab versus sunitinib for patients with untreated renal cell carcinoma (IMmotion 151) were published in The Lancet last month. The study involved 915 patients, of which 40% were positive for PD-L1 biomarkers. In the PD-L1 positive group of patients, the combination of atezolizumab plus bevacizumab was […]

read more

ASCO GU 2019: Atezolizumab and bevacizumab in non-clear cell kidney cancer and sarcomatoid kidney cancer

Results from this trial for patients with non-clear cell renal cell carcinoma (RCC) or sarcomatoid RCC were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. The combination of atezolizumab and bevacizumab has been shown to be effective in the treatment of clear cell RCC. […]

read more

Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

The combined safety results of two studies with the atezolizumab plus bevacizumab combination were presented at the European Society of Medical Oncology (ESMO) Congress in Munich, Germany last week. The phase 2 IMmotion 150 clinical trial compared the efficacy of the atezolizumab plus bevacizumab combination with atezolizumab alone and sunitinib alone, and then allowed for crossover to […]

read more

ESMO 2018: Cabozantinib in combination with atezolizumab in metastatic kidney cancer

The following video interview from Practice Update discusses the promising results from the phase 1b trial of cabozantinib in combination with atezolizumab for metastatic renal cell carcinoma (RCC), the results of which were presented at the European Society of Medical Oncology (ESMO) conference in Munich, Germany last week. Watch the video interview from Practice Update here

read more

ESMO 2018: Cabozantinib/atezolizumab combination shows encouraging clinical activity for untreated advanced RCC

Results from the phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in people with previously untreated advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich over the weekend. This dose-escalation study primarily looked at the safety of the cabozantinib + atezolizumab combination in […]

read more

Patient-reported outcomes for atezolizumab plus bevacizumab combination

Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed the atezolizumab plus bevacizumab combination versus sunitinib in metastatic renal cell carcinoma (RCC) patients, were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week. In the IMmotion151 clinical trial, the combination of atezolizumab plus bevacizumab improved progression-free survival […]

read more
Showing 11 to 20 of 30 results
  TOP